Dako, Omnyx work together on pathology
PITTSBURGH, Penn. – Dako, a
Danish-based world leader in tissue-based cancer diagnostics, and Omnyx,
a leader in digital pathology solutions, announced that they have
entered into a three-year agreement to develop clinical algorithms for
digital pathology. The aim is to support pathologists in generating even
more accurate, objective and reproducible diagnostic results.
Under the agreement, Dako will utilize its expertise in staining and
image analysis to develop image analysis algorithms, which will be
incorporated into the Omnyx digital pathology platform as part of
Omnyx’s overall strategy of providing pathologists with a comprehensive
digital work environment. The algorithms developed under the agreement
will be specifically optimized for Dako’s breast cancer panel of
immunohistochemical and in-situ hybridization tests.
“Digital pathology offers significant potential to improve the quality
of cancer diagnosis by improving the consistency of test
interpretation,” said Dr. Michael Becich, University of Pittsburgh
Medical Center in Pittsburgh, Pennsylvania. “The Omnyx/Dako partnership
will help standardize the reagent-to-result process and enhance the
ability of pathologists to interpret breast cancer tests”.
Digital pathology is enabled by imaging systems and computer technology
that allow for the digitization of glass slides and efficient management
of the resulting image data. It enables pathologists to improve
productivity by reviewing tissue sections without handling traditional
glass slides and to interpret tissue based test results more objectively
with the help of image analysis algorithms. Digital pathology also holds
tremendous potential for standardizing test interpretation and for
improving accuracy in cancer diagnostics.
“Dako is committed to improving patient care by finding ways to further
enhance the standards and accuracy in cancer diagnostics. This agreement
with Omnyx is another important step in the implementation of our
strategy by joining forces with strong digital pathology partners.
Digital pathology is important as it offers great potential to improve
the quality of cancer diagnosis and care by helping standardize test
interpretation to the benefit of pathologists and their patients,” said
Lars Holmkvist, CEO of Dako.
“Omnyx sees a future where algorithms help pathologists make better
clinical decisions. Our partnership with Dako will allow us to provide
reliable, high-performance IHC algorithms to clinicians who use Dako
tests. Enabling algorithms within the context of a complete digital
workflow environment provides pathologists with a powerful set of tools
to improve both confidence and efficiency,” commented Gene Cartwright,
CEO of Omnyx.
Immunohistochemistry refers to the process of localizing antigens (e.g.
proteins) in cells of a tissue section, exploiting the principle of
antibodies binding specifically to antigens in biological tissues.
Immunohistochemistry and in-situ hybridization, which uses a DNA or RNA
strand to identify abnormalities, are both widely used in the diagnosis
of cancerous cells and also in the process of predicting a patient’s
response to various treatments.
Dako, based in Denmark, is a global leader in tissue-based cancer
diagnostics. Hospital and research laboratories worldwide use Dako’s
know-how, reagents, instruments and software to make precise diagnoses
and determine the most effective treatment for patients suffering from
cancer. Employing more than 1000 people and being present in more than
80 countries, Dako covers essentially all of the anatomic pathology
markets globally. Dako is owned by a private equity fund, EQT.
Omnyx, LLC is a joint venture of GE Healthcare and The University of
Pittsburgh Medical Center with locations in Pittsbugh, PA and
Piscataway, NJ. The company is developing an enterprise platform to
transform the scope of pathology to an all-digital workflow. The company
will sell their digital pathology platform to clinical labs and offer an
enterprise software platform for image management, workflow automation,
image analysis algorithms and system integration along with its high
speed whole-slide scanners. Close collaboration with pathologists at
UPMC and other institutions along with their relationship with GE
Healthcare allows Omnyx to focus its innovation on the needs of anatomic
pathologists worldwide. Omnyx digital pathology products are currently
in development and have not yet been cleared by the FDA.
Posted July 29, 2010